Pearson’s CEO Andy Bird (pictured) has announced that the educational-publishing company will overhaul its business to draw a line under a “tumultuous decade”, says Bethan Staton in the Financial Times: it “issued seven profit warnings in as many years”.
The plan is to shift from selling mainly to schools and colleges towards selling directly to consumers, including students. The company is also looking to take advantage of what it sees as the growing demand for “lifelong learning” as workers start to spend more time continuously upgrading their skills throughout their careers. These changes may cause Pearson some short-term pain, says Simon Duke in The Times. Bird says restructuring the company into five divisions, including a new consumer division, will cost “between £40m and £70m this year”. At the same time the decision to slash office space, to take advantage of a move towards remote working, will “reduce reported profits by about £130m this year”, although it will also cut long-term overheads.
Bird will have to “move quickly to keep investors on side”, especially when patience has already been “tested” over his pay packet, says Ben Woods in The Daily Telegraph. Another concern is whether Pearson’s success in selling to the college market can extend to the “super competitive” lifelong-learning market, especially since the company has “stoked up expectations” of a “Netflix of Education”-style revolution before, only to leave investors “wanting”. Still, it’s a necessary gamble: lifelong learning “is clearly where the growth is”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
GSK share price surges after $2.2bn Zantac drug settlementGSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
-
Will the Autumn Budget impact investment markets?Keir Starmer has warned the Autumn Budget will be “painful”. Will it impact investment markets and should you tweak your portfolio before 30 October?
-
Qualcomm could acquire rival Intel – but securing the deal won't be easyA tie-up between Qualcomm and its semiconductor rival Intel would be a coup. But multiple regulatory and commercial hurdles lie ahead.
-
Modi’s reforms set Indian stocks on fireIndian stocks pass a new milestone, but global fund managers are holding back. Are there signs of overheating?
-
How to invest in the quiet market monthsHere's how to invest in the quiet market months, since “sell in May” hasn’t paid off this year.
-
Spire Healthcare: invest in the booming demand for private healthcareSpire Healthcare is one of the few listed companies benefiting from the growing trend in private healthcare. Should you invest?
-
Are insurance companies a good investment?Costs may be soaring but the insurance sector is currently going through one of its most profitable periods. The market has been slow to realise the opportunity here
-
Dr Martens shares slump: should you give it the boot?Over the past three years, Dr Martens has fallen out of fashion. Are the shares worth a look?
-
Google's legal challenges – could it be broken up?Google is fending off legal challenges from both the EU and the US. But would breaking it up actually work?
-
Fast-growing bargain stocks the market has missedA professional investor recommends attractive stocks to invest in. This week: Dan Higgins, portfolio manager, Majedie Investments, highlights three favourites
